Quit Genius, a San Francisco-based digital provider specializing in addiction treatment, recently announced it has raised $11 million in a Series A funding round. The investment marks an important milestone for the company as it aims to expand beyond its initial focus on smoking and vaping cessation to tackle broader addiction challenges, including alcohol and substance use disorders.
The latest funding round was led by Octopus Ventures, a British venture capital firm known for investing in health care innovation. Other participants included Y Combinator, Startup Health, Triple Point Ventures, and Serena Ventures, the early-stage investment firm founded by tennis legend Serena Williams. With this infusion of capital, Quit Genius’s total funding now stands at $13.6 million, according to Crunchbase.
A Digital Platform for Smoking and Vaping Cessation
Quit Genius was founded in 2015 with the mission of using digital technology to make addiction treatment more accessible and effective. The company’s platform focuses on cognitive behavioral therapy (CBT), which is widely recognized as one of the most effective methods for treating addictive behaviors.
Through its app, users can access CBT modules tailored to smoking and vaping cessation, receive one year of personalized coaching support, and utilize progress-tracking tools. One of the platform’s unique features is its integration with a carbon monoxide breath sensor, which allows individuals to monitor their smoking status and verify progress in real time.
In addition, Quit Genius directs users toward nicotine replacement therapies and other evidence-based resources to support long-term cessation. This combination of digital therapy, coaching, and practical tools provides a comprehensive framework for breaking the cycle of nicotine addiction.
Demonstrated Success Through Evidence-Based Results
Quit Genius has touted strong outcomes in its mission to help individuals quit smoking. According to peer-reviewed studies shared by the company, 53% of Quit Genius users were able to permanently stop smoking. This success rate is more than double that of traditional face-to-face interventions and significantly higher than those who attempt to quit “cold turkey,” where only a small percentage succeed long-term.
These results underscore the potential of digital-first approaches to addiction treatment. By combining clinical strategies like CBT with accessible technology, Quit Genius bridges a gap for individuals who may not otherwise seek in-person treatment. The evidence also suggests that digital programs can deliver outcomes that rival or even surpass traditional methods.
Expansion Into Alcohol and Substance Use Disorder Treatment
While smoking and vaping have been Quit Genius’s initial focus, the company has ambitious plans to expand its offerings. With the new $11 million in funding, Quit Genius intends to broaden its platform to include treatment for alcohol use disorder and other substance use disorders (SUD).
The expansion is a natural progression, given the rising demand for accessible addiction treatment solutions. Millions of Americans struggle with alcohol and substance use disorders, yet many do not receive the treatment they need. Barriers such as stigma, cost, and geographic limitations often prevent people from accessing traditional rehab or therapy programs.
By leveraging its existing digital infrastructure, Quit Genius is well-positioned to extend its evidence-based model to these areas. The goal is to make treatment more scalable and widely available, particularly as digital health adoption continues to grow.
The Role of Venture Capital in Digital Health Innovation
The support from Octopus Ventures and other investors highlights the increasing recognition of digital health as a vital sector within health care. Venture capital firms have increasingly turned their attention to mental health and addiction-focused startups, driven by both the societal need and the economic opportunity.
The global addiction treatment industry is valued at over $40 billion, with growing demand for services addressing both substance use and behavioral addictions. At the same time, technology-driven solutions offer scalability that traditional in-person programs often cannot achieve.
By investing in Quit Genius, these firms are not only backing a promising company but also signaling confidence in digital behavioral health solutions as part of the future of addiction treatment.
Celebrity Backing from Serena Ventures
An additional point of interest in this funding round is the participation of Serena Ventures, the investment firm founded by tennis champion Serena Williams. Known for backing diverse and socially impactful companies, Serena Ventures’ involvement brings both visibility and credibility to Quit Genius.
Williams has long been an advocate for wellness and empowerment, and her firm’s investment reflects an interest in supporting companies that tackle pressing health issues. For Quit Genius, this association may help attract further attention from both consumers and partners within the health care ecosystem.
The Growing Need for Digital Addiction Treatment
The timing of Quit Genius’s expansion is especially relevant given global health challenges such as the COVID-19 pandemic, which have heightened stress, isolation, and substance use for many individuals. During periods when in-person treatment was limited or inaccessible, digital solutions became essential.
Even beyond the pandemic, digital addiction treatment is likely to remain a critical component of health care delivery. It offers convenience, privacy, and flexibility that align with modern lifestyles while also addressing the gaps in traditional care systems.
Quit Genius’s success demonstrates how technology can transform addiction treatment into something more engaging and effective for users. By offering structured therapy, coaching, and real-time progress tracking, the platform has the potential to reach populations that might otherwise go untreated.
Challenges and Future Opportunities
While Quit Genius has seen promising results, scaling its services to include alcohol and substance use disorder treatment will present new challenges. These conditions often involve more complex medical, psychological, and social factors compared to nicotine addiction.
Developing digital programs that are both effective and clinically responsible for SUD treatment will require careful design, testing, and partnerships with health care professionals. Regulatory considerations may also come into play, especially if the platform expands into areas like medication-assisted treatment (MAT).
However, the opportunities are substantial. By diversifying its offerings, Quit Genius could become a leading digital provider in the addiction treatment space, serving as a model for how technology can complement and expand access to behavioral health care.
Looking Ahead
With $11 million in new funding and growing interest from investors, Quit Genius is poised for significant growth. Its expansion into alcohol and substance use disorder treatment reflects both the scale of the addiction crisis and the role that digital solutions can play in addressing it.
As more individuals seek accessible, evidence-based care, platforms like Quit Genius may redefine how addiction treatment is delivered. With strong outcomes, investor support, and a growing user base, Quit Genius represents an important step forward in digital behavioral health innovation.
Ultimately, the company’s success highlights the potential for technology to close treatment gaps, empower individuals, and improve long-term recovery outcomes. As it continues to evolve, Quit Genius could set a new standard for how addiction treatment is approached in the digital age.
